MA31521B1 - Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central - Google Patents
Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et centralInfo
- Publication number
- MA31521B1 MA31521B1 MA32515A MA32515A MA31521B1 MA 31521 B1 MA31521 B1 MA 31521B1 MA 32515 A MA32515 A MA 32515A MA 32515 A MA32515 A MA 32515A MA 31521 B1 MA31521 B1 MA 31521B1
- Authority
- MA
- Morocco
- Prior art keywords
- nervous system
- diseases
- central
- dihydropenzo
- dioxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Abstract
La présente invention concerne des composés de formule (i). Dans ladite formule, x, z, r1-r4 et m sont tels que définis dans les revendications. Lesdits composés présentent une activité antagoniste envers les alpha2c, et peuvent par conséquent être utilisés pour traiter des maladies et des états du système nerveux périphérique et du système nerveux central (snc).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95098307P | 2007-07-20 | 2007-07-20 | |
PCT/FI2008/000090 WO2009013390A1 (fr) | 2007-07-20 | 2008-07-18 | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31521B1 true MA31521B1 (fr) | 2010-07-01 |
Family
ID=39884455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32515A MA31521B1 (fr) | 2007-07-20 | 2010-01-15 | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central |
Country Status (32)
Country | Link |
---|---|
US (3) | US8492549B2 (fr) |
EP (1) | EP2176252B1 (fr) |
JP (1) | JP5460590B2 (fr) |
KR (1) | KR101535059B1 (fr) |
CN (1) | CN101842369B (fr) |
AR (1) | AR069271A1 (fr) |
AU (1) | AU2008278924B2 (fr) |
BR (1) | BRPI0814529B8 (fr) |
CA (1) | CA2693804C (fr) |
CL (1) | CL2008002114A1 (fr) |
CO (1) | CO6331473A2 (fr) |
CY (1) | CY1115789T1 (fr) |
DK (1) | DK2176252T3 (fr) |
EA (1) | EA017554B1 (fr) |
ES (1) | ES2502215T3 (fr) |
GE (1) | GEP20125538B (fr) |
HK (1) | HK1148530A1 (fr) |
HR (1) | HRP20141156T1 (fr) |
IL (1) | IL202964A (fr) |
MA (1) | MA31521B1 (fr) |
MY (1) | MY153872A (fr) |
NZ (1) | NZ582432A (fr) |
PE (1) | PE20090890A1 (fr) |
PL (1) | PL2176252T3 (fr) |
PT (1) | PT2176252E (fr) |
RS (1) | RS53571B1 (fr) |
SI (1) | SI2176252T1 (fr) |
TN (1) | TN2010000029A1 (fr) |
TW (1) | TWI457122B (fr) |
UA (1) | UA100695C2 (fr) |
WO (1) | WO2009013390A1 (fr) |
ZA (1) | ZA201000314B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物 |
US8492372B2 (en) * | 2008-04-29 | 2013-07-23 | Integrated Research Laboratories Sweden Ab | Modulators of dopamine neurotransmission |
MX2010011724A (es) * | 2008-04-29 | 2010-11-30 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
JP2011519839A (ja) * | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
TW201024282A (en) * | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
US20130267699A1 (en) | 2011-06-24 | 2013-10-10 | California Institute Of Technology | Quaternary heteroatom containing compounds |
US8822679B2 (en) * | 2011-06-24 | 2014-09-02 | California Institute Of Technology | Quaternary heteroatom containing compounds |
US9518034B2 (en) | 2013-10-14 | 2016-12-13 | California Institute Of Technology | Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof |
US10421696B2 (en) | 2014-12-18 | 2019-09-24 | California Institute Of Technology | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation |
CN105985389B (zh) * | 2015-03-06 | 2019-03-19 | 北京大学 | 苯乙醇苷类似物及其合成方法和应用 |
CN107922373A (zh) | 2015-03-27 | 2018-04-17 | 加利福尼亚技术学院 | 使用低催化剂浓度和稳定的预催化剂的不对称催化脱羧烷基烷基化 |
TWI704145B (zh) * | 2015-06-05 | 2020-09-11 | 芬蘭商奧利安公司 | 新醫藥化合物 |
EP3426391A4 (fr) | 2016-03-11 | 2019-08-28 | California Institute of Technology | Compositions et procédés d'acylation de lactames |
EA201990158A1 (ru) | 2016-06-29 | 2019-05-31 | Орион Корпорейшн | Производные бензодиоксана и их фармацевтическое применение |
CA3055215A1 (fr) * | 2017-03-12 | 2018-09-20 | Xiaodong Wang | Amines polycycliques utilisees comme modulateurs des recepteurs opioides |
US10358422B2 (en) | 2017-11-01 | 2019-07-23 | California Institute Of Technology | Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols |
GB201801130D0 (en) | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
US11214568B2 (en) | 2018-10-18 | 2022-01-04 | California Institute Of Technology | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same |
WO2023131640A1 (fr) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | ANTAGONISTES DE SOUS-TYPE C DE α2-ADRÉNOCEPTEUR POUR LE TRAITEMENT DE L'APNÉE DU SOMMEIL |
KR20230114646A (ko) * | 2022-01-25 | 2023-08-01 | 재단법인 한국파스퇴르연구소 | 벤조다이옥세인 유도체 화합물 및 이의 의약 용도 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2056046A (en) | 1933-05-19 | 1936-09-29 | Rhone Poulenc Sa | Manufacture of bases derived from benz-dioxane |
US3635982A (en) | 1969-04-08 | 1972-01-18 | American Home Prod | Amino-substituted-quinoxalinyloxazolidines and -oxazines |
GB1411531A (en) | 1972-10-24 | 1975-10-29 | Lafon Labor | Amino derivatives of 1,4-benzodioxan |
JPS5163193A (ja) * | 1974-11-26 | 1976-06-01 | Yoshitomi Pharmaceutical | Tetorahidoropirazoropirijinkagobutsuno seizoho |
US4039676A (en) | 1975-06-23 | 1977-08-02 | Ciba-Geigy Corporation | 2-piperidinoalkyl-1,4-benzodioxans |
US4329348A (en) * | 1979-02-26 | 1982-05-11 | Ciba-Geigy Corporation | N-Oxacyclic-alkylpiperidines as psychostimulants |
HU181575B (en) | 1980-10-03 | 1983-10-28 | Richter Gedeon Vegyeszet | Process for preparing 3-chloro-propyl-malonic acid ester and cyano-acetic acid ester derivatives |
FR2525600A1 (fr) * | 1982-04-21 | 1983-10-28 | Bouchara Emile | Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
GB2167408B (en) | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
DD250930A1 (de) | 1986-06-08 | 1987-10-28 | Isis Chemie Zwickau Veb | Verfahren zur herstellung neuer tetrahydroisochinolinderivate |
US4957928A (en) | 1986-06-26 | 1990-09-18 | Ciba-Geigy Corporation | Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds |
KR900701774A (ko) | 1988-08-16 | 1990-12-04 | 제임스 제이. 플린 | 살진균성 벤조디옥산 아민 유도체 |
JPH06507392A (ja) | 1991-02-26 | 1994-08-25 | エイアールシー 1,インコーポレイテッド | 交感神経性の持続性疼痛の治療のための組成物および方法 |
GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
GB9514380D0 (en) | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
FR2744451B1 (fr) | 1996-02-01 | 1998-04-24 | Pf Medicament | Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique |
EP0983239A1 (fr) | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Nouveaux composes heterocycliques |
US5902807A (en) | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
IL136388A0 (en) | 1997-12-04 | 2001-06-14 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Orion Yhtymae Oyj | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
CA2422055A1 (fr) * | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Ligands pour les recepteurs de monoamine et transporteurs, et procedes d'utilisation de ces derniers |
WO2003082866A1 (fr) | 2002-04-03 | 2003-10-09 | Orion Corporation | Composes polycycliques comme antagonistes puissants des recepteurs $g(a)2-adrenergiques |
WO2004067513A1 (fr) | 2003-01-27 | 2004-08-12 | Oy Juvantia Pharma Ltd | Antagonistes pour recepteurs alpha-2 adrenergiques |
TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物 |
JP5163193B2 (ja) | 2008-03-13 | 2013-03-13 | セイコーエプソン株式会社 | プリンタシステム及びプリンタシステムにおける制御方法 |
-
2008
- 2008-07-02 TW TW097124840A patent/TWI457122B/zh active
- 2008-07-17 AR ARP080103087A patent/AR069271A1/es active IP Right Grant
- 2008-07-17 PE PE2008001216A patent/PE20090890A1/es active IP Right Grant
- 2008-07-17 CL CL2008002114A patent/CL2008002114A1/es unknown
- 2008-07-18 ES ES08787689.2T patent/ES2502215T3/es active Active
- 2008-07-18 CN CN200880025445.8A patent/CN101842369B/zh active Active
- 2008-07-18 AU AU2008278924A patent/AU2008278924B2/en active Active
- 2008-07-18 EA EA201070169A patent/EA017554B1/ru not_active IP Right Cessation
- 2008-07-18 NZ NZ582432A patent/NZ582432A/en unknown
- 2008-07-18 MY MYPI2010000086A patent/MY153872A/en unknown
- 2008-07-18 KR KR1020107003606A patent/KR101535059B1/ko active IP Right Grant
- 2008-07-18 EP EP08787689.2A patent/EP2176252B1/fr active Active
- 2008-07-18 UA UAA201001749A patent/UA100695C2/ru unknown
- 2008-07-18 DK DK08787689.2T patent/DK2176252T3/en active
- 2008-07-18 CA CA2693804A patent/CA2693804C/fr active Active
- 2008-07-18 RS RSP20140510 patent/RS53571B1/en unknown
- 2008-07-18 PL PL08787689T patent/PL2176252T3/pl unknown
- 2008-07-18 WO PCT/FI2008/000090 patent/WO2009013390A1/fr active Application Filing
- 2008-07-18 SI SI200831313T patent/SI2176252T1/sl unknown
- 2008-07-18 US US12/668,918 patent/US8492549B2/en active Active
- 2008-07-18 BR BRPI0814529A patent/BRPI0814529B8/pt active IP Right Grant
- 2008-07-18 GE GEAP200811693A patent/GEP20125538B/en unknown
- 2008-07-18 JP JP2010516529A patent/JP5460590B2/ja active Active
- 2008-07-18 PT PT87876892T patent/PT2176252E/pt unknown
-
2009
- 2009-12-24 IL IL202964A patent/IL202964A/en active IP Right Grant
-
2010
- 2010-01-15 TN TNP2010000029A patent/TN2010000029A1/fr unknown
- 2010-01-15 ZA ZA201000314A patent/ZA201000314B/xx unknown
- 2010-01-15 MA MA32515A patent/MA31521B1/fr unknown
- 2010-01-19 CO CO10004690A patent/CO6331473A2/es active IP Right Grant
-
2011
- 2011-03-21 HK HK11102788.9A patent/HK1148530A1/xx unknown
-
2013
- 2013-06-14 US US13/917,745 patent/US8697723B2/en active Active
-
2014
- 2014-02-27 US US14/192,131 patent/US8809536B2/en active Active
- 2014-11-26 CY CY20141100982T patent/CY1115789T1/el unknown
- 2014-11-27 HR HRP20141156AT patent/HRP20141156T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
MA29140B1 (fr) | Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10 | |
MA31766B1 (fr) | Composés organiques | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
TNSN07021A1 (fr) | Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc | |
MA32655B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MA27933A1 (fr) | Inhibiteurs de l'activite de akt | |
EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
UA87856C2 (ru) | Алкильные производные как модуляторы метаботропных рецепторов глутамата | |
MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
GB0510143D0 (en) | Novel compounds A1 | |
EA201000314A1 (ru) | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны | |
TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
MA33238B1 (fr) | Composés utilisés comme antagonistes de la bradykinine b1 | |
NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
ATE304533T1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA38091A2 (fr) | Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine | |
MA27852A1 (fr) | Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique |